Hublo secures €40 million reinvestment led by Revaia
Hublo, a Paris-based provider of workforce management software for healthcare institutions, has secured a €40 million reinvestment vehicle backed by growth investor Revaia. The transaction is designed to extend Revaia’s support beyond its initial holding period, following Hublo’s sale in 2025 to Five Arrows, the alternative asset investment arm of Rothschild & Co.
The reinvestment vehicle brings together investors from Europe, the UK and the US, and enables both existing and new backers to invest alongside the company’s current majority shareholder and management team. Unlike a traditional primary fundraising round that mainly injects new capital into operations, a reinvestment vehicle typically reflects an ownership-driven commitment meant to support long-term value creation after an exit event.
Leadership: “A long-term partnership built on trust and alignment”
Antoine Loron, co-founder and co-CEO of Hublo, said the move signals continuity as the company enters its next stage. “Revaia’s continued commitment to us is a continuation of a long-term partnership built on trust and alignment,” he said, adding that the decision to reinvest alongside the new majority shareholder “demonstrates their belief in our trajectory and strengthens the stability of our shareholder base for the next stage of our development.”
Alice Albizzati, Founding Partner at Revaia, framed the reinvestment as a vote of confidence in both execution and the roadmap ahead. She said the vehicle “extends the support we have provided to Hublo since 2021,” while also allowing the firm to “bring in new investors for the next phase of value creation.”
From Covid-era merger to large-scale healthcare workforce platform
Founded in 2016, Hublo emerged from the merger of Whoog and MedGo during the Covid period, when staffing shortages and operational strain intensified across Europe’s healthcare systems. The company’s platform is positioned as an end-to-end workforce and talent management solution for healthcare providers, covering recruitment, scheduling, internal mobility and team communication.
According to the company, the software centralises and optimises both ad-hoc and recurring staffing needs for hospitals, clinics, nursing homes and other healthcare organisations. By 2025, Hublo reported that its tools were used by more than 22,000 managers across over 5,000 facilities, benefiting around 1 million healthcare professionals. The company also cited average time savings of roughly 2.5 hours per day per user—an efficiency claim that resonates in a sector where administrative burden is a persistent challenge.
Revaia’s path: scaling, consolidation, and a first fund exit
Revaia first acquired a significant stake in Hublo in July 2021, backing the company as it expanded its product footprint and commercial reach. The investor’s support was structured around three main levers: broadening the product into a comprehensive workforce and talent management platform; strengthening go-to-market execution across public and private healthcare institutions; and pursuing a consolidation strategy that included three acquisitions integrated during the period.
That playbook helped Hublo quadruple annual recurring revenue and reach operational break-even ahead of schedule, according to the companies. In July 2025, Five Arrows finalised its strategic investment after a competitive process, marking the first exit for the Revaia Growth I fund.
The new reinvestment comes after Revaia closed its Revaia Growth II fund at €250 million in 2025, underscoring the firm’s continued focus on later-stage European technology businesses and its capacity to support portfolio companies through ownership transitions.
How the deal compares with recent European HealthTech rounds
The €40 million reinvestment stands out against recent funding activity in adjacent areas of European HealthTech, where rounds have generally been smaller. In September 2025, Warsaw-based Doctor.One raised €4 million to expand an asynchronous care platform for chronic patients. Antwerp startup Mindoo secured €5 million in Seed funding to reduce administrative workload for hospital and medical staff using AI agents—an approach closely aligned with Hublo’s focus on operational efficiency.
Elsewhere, Zurich-based Ahead Health raised €5.1 million to scale preventive healthcare services through clinic partnerships, while UK longevity startup GlycanAge closed a €7.4 million round to commercialise glycan-based ageing diagnostics. Together, those financings total about €21.5 million—roughly half the size of Hublo’s reinvestment vehicle—highlighting the later-stage nature of this commitment and its emphasis on post-exit continuity rather than early growth capital alone.
What comes next for Hublo
With Five Arrows as majority shareholder and Revaia reaffirming its position via the reinvestment vehicle, Hublo enters 2026 with a reinforced shareholder base and additional resources to pursue its product and expansion agenda. While the company has not detailed specific deployment plans for the reinvestment vehicle, the structure signals a longer runway for scaling, potential further consolidation, and continued investment in tools that reduce operational friction for healthcare institutions.
For a sector under pressure from staff shortages, cost constraints and administrative overload, the deal illustrates how investors are increasingly backing platforms that promise measurable efficiency gains—and how post-exit ownership structures can be engineered to keep experienced growth backers involved for the next chapter.
Related
